Antagonistic drug interactions protect commensal Bacteroidaceae from macrolides via an RND-type efflux pump
Open Access
- 9 December 2025
- journal article
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2596806
Abstract
Antibiotics are essential to modern medicine, but their broad-spectrum activity can unintentionally disrupt the gut microbiota. This collateral damage may be alleviated by antagonistic drug interactions, in which specific compounds used in combination therapies selectively protect beneficial gut microbes from antibiotic activity. Using efflux pump inhibitors, transcriptomic and proteomic analyses, and targeted gene deletions, we show that a variety of non-antibiotic pharmaceuticals-from diverse therapeutic classes and at sub-inhibitory concentrations-can protect multiple Bacteroidales species from macrolide antibiotics. In Bacteroidaceae, this protection is mediated by a resistance-nodulation-division (RND)-type efflux pump, which is induced by the non-antibiotic drug but not by macrolides alone. Notably, protection persists even after the non-antibiotic drug is removed, and prolonged exposure results in stable macrolide resistance that is dependent on the RND-type efflux pump. Our findings illustrate how non-antibiotic drugs can inadvertently activate otherwise silent detoxification systems in gut microbes, uncovering resistance mechanisms that arise without antibiotic selection or gene transfer. While this can be harnessed to protect the microbiome during antibiotic therapy, it also reveals hidden resistance phenotypes that may escape detection in standard antimicrobial resistance assays.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (EXC 2124, MA 8164/1-2, MA 8164/3-1))
- Deutsches Zentrum für Infektionsforschung (CEGIMIR, TTU06.709)
- European Research Council (101076015)
- Kempestiftelserna
- de.NBI Cloud (031A532B, 031A533A+B, 031A534A, 031A535A-D)
This publication has 63 references indexed in Scilit:
- Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced ColitisInfection and Immunity, 2012
- Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter rodentium -Induced ColitisInfection and Immunity, 2011
- Antibiotic Sensitivity Profiles Determined with an Escherichia coli Gene Knockout Collection: Generating an Antibiotic Bar CodeAntimicrobial Agents and Chemotherapy, 2010
- Novel Macrolide-Specific ABC-Type Efflux Transporter in Escherichia coliJournal of Bacteriology, 2001
- Antibiotic Susceptibility Profiles of Escherichia coli Strains Lacking Multidrug Efflux Pump GenesAntimicrobial Agents and Chemotherapy, 2001
- The role of efflux in macrolide resistanceDrug Resistance Updates, 2000
- Efflux pumps and drug resistance in Gram-negative bacteriaTrends in Microbiology, 1994
- Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathwayJournal of Bacteriology, 1993
- Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agentEuropean Journal of Clinical Pharmacology, 1981
- The pharmacology of hypouricemic effect of benzbromarone.1975